Ibrutinib combination therapy

A method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a combination comprising:

• a. ibrutinib;
• and
• b. an anticancer agent, wherein the anticancer agent is a glucocorticoid, a vinca alkaloid, an anti-metabolite, a DNA damaging agent, lenalidomide, rituximab, or a PKC perturbagen,
• wherein the combination provides a synergistic therapeutic effect compared to administration of ibrutinib or the anticancer agent alone.

A method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a combination comprising:

• a. ibrutinib;
• and
• b. an anticancer agent, wherein the anticancer agent inhibits a B-cell receptor pathway kinase selected from Lyn/Fyn, Syk, PI3K, PKCβ, and IKK,
• wherein the combination provides a synergistic therapeutic effect compared to administration of ibrutinib or the anticancer agent alone.

A method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a combination comprising:

• a. ibrutinib;
• and
• b. an anticancer agent, wherein the anticancer agent inhibits the 20s proteasome, IRF-4, IRAK4, EZH2, CXCR4, CXCR5, GLS, cyclin dependent kinase 4/6 (CDK4/6), topoisomerase II, PLK;
• DNA methyltransferase, the Ras/MAPK pathway, or FGFR1 tyrosine kinase,
• wherein the combination provides a synergistic therapeutic effect compared to administration of ibrutinib or the anticancer agent alone.

A pharmaceutical composition comprising:

• a. a therapeutically effective amount of ibrutinib;
• and
• b. an anticancer agent, wherein the anticancer agent inhibits Bcl-2, Janus kinase 2 (JAK2), Anaplastic lymphoma kinase (ALK), or heat shock protein 90 (Hsp90);
• or the anticancer agent is a glucocorticoid, a vinca alkaloid, an anti-metabolite, a DNA damaging agent, lenalidomide, rituximab, or a PKC perturbagen;
• or the anticancer agent inhibits a B-cell receptor pathway kinase selected from Lyn/Fyn, Syk, PI3K, PKCβ, and IKK;
• or the anticancer agent inhibits the 20s proteasome, IRF-4, IRAK4, EZH2, CXCR4, CXCR5, GLS, cyclin dependent kinase 4/6 (CDK4/6), topoisomerase II, PLK;
• DNA methyltransferase, the Ras/MAPK pathway, or FGFR1 tyrosine kinase;
• or the anticancer agent is selected from AZD0503, dasatinib and nilotinib, and JNJ-20;
• wherein the combination provides a synergistic therapeutic effect compared to administration of ibrutinib or the anticancer agent alone.